Combination of Caspy2 and IP-10 gene therapy significantly improves therapeutic efficacy against murine malignant neoplasm growth and metastasis

Human Gene Therapy

Volumn 23, Issue 8, 2012, Pages 837-846

  Zhang, Na ^a   Yang, Yang ^a   Cheng, Lin ^a   Zhang, Xiao Mei ^a   Zhang, Shuang ^a   Wang, Wei ^a   Liu, Sheng Yong ^a   Wang, Shu Ya ^a   Wang, Rui Bo ^a   Xu, Wen Jing ^a   Dai, Lei ^a   Yan, Nv ^a   Fan, Ping ^a   Dai, Li Xia ^a   Tian, Hong Wei ^a   Liu, Lei ^a   Deng, Hong Xin ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD31 ANTIGEN; CHOLESTEROL; GAMMA INTERFERON INDUCIBLE PROTEIN 10; KI 67 ANTIGEN; NANOPARTICLE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; GENE THERAPY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NICK END LABELING; NONHUMAN; RECOMBINANT PLASMID; T CELL DEPLETION; TUMOR CELL; TUMOR GROWTH;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CASPASES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CXCL10; COLONIC NEOPLASMS; FEMALE; GENETIC THERAPY; LIPOSOMES; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84865233140     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.136     Document Type: Article

References (27)

1. Cross, D., and Burmester, J.K. (2006). Gene therapy for cancer treatment: Past, present and future. Clin. Med. Res. 4, 218-227.
2. Danussi, C., Spessotto, P., Petrucco, A., et al. (2008). Emilin1 deficiency causes structural and functional defects of lymphatic vasculature. Mol. Cell. Biol. 28, 4026-4039.
3. Ding, H.F., and Fisher, D.E. (2002). Induction of apoptosis in cancer: New therapeutic opportunities. Ann. Med. 34, 451-469.
4. Farber, J.M. (1997). Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukoc. Biol. 61, 246-257.
5. Folkman, J. (2006). Angiogenesis. Annu. Rev. Med. 57, 1-18.
6. Fujita, M., Zhu, X., Ueda, R., et al. (2009). Effective immu-notherapy against murine gliomas using type 1 polarizing dendritic cells: Significant roles of CXCL10. Cancer Res. 69, 1587.
7. Hamzah, J., Jugold, M., Kiessling, F., et al. (2008). Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453, 410-414.
8. Liu, L., Deng, H., Wang, Y., et al. (2009). A novel strategy for tumour therapy combining cell apoptosis and active immunity induced by Caspy2, a zebrafish caspase. J. Cell. Mol. Med. 13, 2271-2281.
9. Loetscher, M., Loetscher, P., Brass, N., et al. (1998). Lymphocyte-specific chemokine receptor CXCR3: Regulation, chemokine binding and gene localization. Eur. J. Immunol. 28, 3696-3705.
10. Luo, Y., Zhou, H., Mizutani, M., et al. (2005). A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence. Cancer Res. 65, 3419-3427.
11. Maru, S.V., Holloway, K.A., Flynn, G., et al. (2008). Chemokine production and chemokine receptor expression by human glioma cells: Role of CXCL10 in tumour cell proliferation. J. Neuroimmunol. 199, 35-45.
12. Masumoto, J., Zhou, W., Chen, F.F., et al. (2003). Caspy, a zeb-rafish caspase, activated by ASC oligomerization is required for pharyngeal arch development. J. Biol. Chem. 278, 4268-4276.
13. Michaeli, D. (2005). Vaccines and monoclonal antibodies. Semin. Oncol. 32, 82-86.
14. Negron, J.F., and Lockshin, R.A. (2004). Activation of apoptosis and caspase-3 in zebrafish early gastrulae. Dev. Dynam. 231, 161-170.
15. Neville, L.F., Mathiak, G., and Bagasra, O. (1997). The im-munobiology of interferon-c inducible protein 10 kD (IP-10): A novel, pleiotropic member of the CXC chemokine superfamily. Cytokine Growth Factor Rev. 8, 207-219.
16. Plautz, G.E., Yang, Z.Y., Wu, B., et al. (1993). Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. U.S.A. 90, 4645-4649.
17. Qian, D.Z., Wang, X., Kachhap, S.K., et al. (2004). The his-tone deacetylase inhibitor NVP-LAQ824 inhibits angiogene-sis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 64, 6626-6634.
18. Rosenberg, S.A. (2001). Progress in human tumour immunology and immunotherapy. Nature 411, 380-384.
19. Schirrmacher, V., Haas, C., Bonifer, R., et al. (1999). Human tumor cell modification by virus infection: An efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther. 6, 63-73.
20. Shi, W., Tang, Q., Chen, X., et al. (2009). Antitumor and anti-metastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer. J. Mol. Med. 87, 493-506.
21. Takeda, K., Yamaguchi, N., Akiba, H., et al. (2004). Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 199, 437-448.
22. Tan, K.S.W., and Nasirudeen, A. (2005). Protozoan programmed cell death: Insights from Blastocystis deathstyles. Trends Parasitol. 21, 547-550.
23. Templeton, N.S., Lasic, D.D., Frederik, P.M., et al. (1997). Improved DNA:liposome complexes for increased systemic delivery and gene expression. Nat. Biotechnol. 15, 647-652.
24. Tong, R.T., Boucher, Y., Kozin, S.V., et al. (2004). Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731-3736.
25. + T cell turnover in vivo by IL-12, IL-18, and IFN-c. J. Immunol. 166, 6007-6011.
26. Zhang, X., Deng, H., Zhao, X., et al. (2009). RNA interference-mediated silencing of the phosphatidylinositol 3-kinase catalytic subunit attenuates growth of human ovarian cancer cells in vitro and in vivo. Oncology 77, 22-32.
27. Zhao, J., Wen, Y., Li, Q., et al. (2008). A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus. FASEB J. 22, 4272-4280.